Daniel Bertholet

  • Investment Director, Endeavour Vision, Geneva, Switzerland

    Daniel Bertholet is an Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in Symetis, CeQur, Endoart (sold to Allergan), Thommen Medical (exited), Kuros Biosurgery, Novalar Pharmaceuticals and Neocutis. He also participated in investments and/or follow-on investments in Native Networks, eProject/Daptiv, Paion, Nexx Systems and Novimmune. Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.

  • Conference Info:

     

    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City


    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!